RxDoctor Payments Data

Stephanie Unger

Family · South Bend, INNPI 1255927828

Payments from drug & device makers

$427in general payments, 2019–2025

Across 14 payments — averaging $30.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$168
  • Lilly USA, LLC$112
  • Novo Nordisk$36
  • Medtronic$35
  • Revance Therapeutics, Inc.$20
  • Dexcom, Inc.$18
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$41597%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$427 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$44,844
Medicare patients
112
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$178,883
OzempicSemaglutide73$136,769
TrulicityDulaglutide72$117,909
JardianceEmpagliflozin48$62,140
Humalog Kwikpen U-100Insulin Lispro83$51,717
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/733$51,546
Tresiba Flextouch U-200Insulin Degludec28$48,677
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$35,316
Tresiba Flextouch U-100Insulin Degludec57$32,359
Fiasp FlextouchInsulin Aspart (Niacinamide)28$28,432
Novolog FlexpenInsulin Aspart55$27,598
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$26,093
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$20,634
Gvoke Hypopen 2-PackGlucagon26$20,429
HumalogInsulin Lispro48$19,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$112$315,801238 claims
Novo NordiskOzempic, Novolog$36$140,86490 claims
Boehringer IngelheimJardiance$14$62,14048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →